SCHEMBL9995288

SCHEMBL9995288

Nc1ccc(Oc2ccnc(N)c2[N+](=O)[O-])c(Cl)c1Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.39
SMN1; SMN2 Q16637 3/20 0.38
MEN1 O00255 4/20 0.37
KMT2A Q03164 4/20 0.37
TDP1 Q9NUW8 2/20 0.37
TTR P02766 1/20 0.37
ALB P02768 1/20 0.37
THRB P10828 1/20 0.37
MAPT P10636 6/20 0.37
ALDH1A1 P00352 3/20 0.36
TP53 P04637 2/20 0.36
HTT P42858 3/20 0.36
KDM4E B2RXH2 1/20 0.35
MITF O75030 1/20 0.35
USP2 O75604 1/20 0.35
KEAP1 Q14145 1/20 0.35
NFE2L2 Q16236 1/20 0.35
PDE7A Q13946 1/20 0.35
NPC1 O15118 1/20 0.34
HPGD P15428 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4464797 0.81 ALDH1A1 (0.47) LMNASMN1; SMN2MEN1KMT2ATDP1
SCHEMBL4466811 0.80 SMN1; SMN2 (0.42) LMNASMN1; SMN2MEN1KMT2ATDP1
SCHEMBL1792398 0.80 LMNA (0.41) LMNASMN1; SMN2MEN1KMT2AMAPT
SCHEMBL4458381 0.80 PDE7A (0.48) LMNASMN1; SMN2MEN1KMT2AMAPT
SCHEMBL4463070 0.79 PDE7A (0.44) LMNASMN1; SMN2MEN1KMT2AMAPT
SCHEMBL9995274 0.78 NOS3 (0.36) MET
SCHEMBL12790006 0.77 NPY1R (0.46) SMN1; SMN2MEN1KMT2ATDP1MAPT
SCHEMBL9994987 0.77 MAPT (0.52) SMN1; SMN2MEN1KMT2ATDP1MAPT
SCHEMBL1794970 0.76 ALDH1A1 (0.43) LMNASMN1; SMN2MEN1KMT2AMAPT
SCHEMBL4465527 0.75 SMN1; SMN2 (0.48) LMNASMN1; SMN2MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10358445-B2 Respiratory formulations and compounds for use therein Respivert, Ltd. (GB) 2019-07-23 US disclosed
US-10358445-B2 Respiratory formulations and compounds for use therein Respivert, Ltd. (GB) 2019-07-23 US disclosed
US-20180201611-A1 Respiratory formulations and compounds for use therein RESPIVERT LTD. (GB) 2018-07-19 US disclosed
US-20180201611-A1 Respiratory formulations and compounds for use therein RESPIVERT LTD. (GB) 2018-07-19 US disclosed
US-20180201611-A1 Respiratory formulations and compounds for use therein RESPIVERT LTD. (GB) 2018-07-19 US disclosed
EP-2582700-B1 RESPIRATORY FORMULATIONS CONTAINING P38 MAPK INHIBITORS RESPIVERT LTD (GB) 2016-11-02 EP disclosed
EP-2582700-B1 RESPIRATORY FORMULATIONS CONTAINING P38 MAPK INHIBITORS RESPIVERT LTD (GB) 2016-11-02 EP disclosed
US-8933228-B2 Respiratory formulations and compounds for use therein Respivert, Ltd. (GB) 2015-01-13 US disclosed
US-8933228-B2 Respiratory formulations and compounds for use therein Respivert, Ltd. (GB) 2015-01-13 US disclosed
US-8933228-B2 Respiratory formulations and compounds for use therein Respivert, Ltd. (GB) 2015-01-13 US disclosed
US-20130156826-A1 RESPIRATORY FORMULATIONS AND COMPOUNDS FOR USE THEREIN RESPIVERT LIMITED (GB) 2013-06-20 US disclosed
US-20130156826-A1 RESPIRATORY FORMULATIONS AND COMPOUNDS FOR USE THEREIN RESPIVERT LIMITED (GB) 2013-06-20 US disclosed
US-20130156826-A1 RESPIRATORY FORMULATIONS AND COMPOUNDS FOR USE THEREIN RESPIVERT LIMITED (GB) 2013-06-20 US disclosed
EP-2582700-A2 RESPIRATORY FORMULATIONS AND COMPOUNDS FOR USE THEREIN Respivert Limited (GB) 2013-04-24 EP disclosed
WO-2011158044-A2 RESPIRATORY FORMULATIONS AND COMPOUNDS FOR USE THEREIN RESPIVERT LIMITED (GB) 2011-12-22 WO disclosed
WO-2011158044-A2 RESPIRATORY FORMULATIONS AND COMPOUNDS FOR USE THEREIN RESPIVERT LIMITED (GB) 2011-12-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130156826-A1 RESPIRATORY FORMULATIONS AND COMPOUNDS FOR USE THEREIN TSLP, CCL11, RORB LMNA 2963/4885SMN1; SMN2 1893/4885MEN1 3075/4885
US-10358445-B2 Respiratory formulations and compounds for use therein TSLP, CCL11, RORB LMNA 2963/4885SMN1; SMN2 1893/4885MEN1 3075/4885
US-20180201611-A1 Respiratory formulations and compounds for use therein TSLP, CCL11, RORB LMNA 2963/4885SMN1; SMN2 1893/4885MEN1 3075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.